Lit­tle Evelo sees big promise in its first cut of da­ta from a tiny study on atopic der­mati­tis

Any­one putting to­geth­er an ear­ly-stage tri­al in­volv­ing 24 pa­tients with a big-mar­ket dis­ease like atopic der­mati­tis wants to know one thing: Do they have a drug that’s ac­tive, with re­al po­ten­tial as a ther­a­py?

Evelo $EV­LO just posed that ques­tion, and the an­swer in the da­ta, says chair­man David Ep­stein, is yes.

“The drug starts to work at 2 weeks,” Ep­stein says as he looks at the da­ta. “That’s re­al­ly fast.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER